Bruker Corporation has unveiled the timsMetabo mass spectrometer, designed to significantly enhance sensitivity and specificity in 4D-Metabolomics and 4D-Lipidomics. This breakthrough technology leverages 4D LC-TIMS-MS/MS separations and CCS measurements, offering unparalleled specificity and annotation confidence. A notable feature is the introduction of the 'digital metabolome archive' for AI/ML scaling, supported by the new TIMS Mobility Range Enhancement (MoRE) technology. The QSee™ QC suite, alongside the cloud-based TwinScape™, ensures performance monitoring for reliable metabolomics research. Enhanced TASQ® RealTimeQC capabilities now offer improved data visualization, crucial for intra-batch data quality monitoring. According to Professor Thomas Moritz from the University of Copenhagen, these advancements provide essential quality monitoring, supporting informed decision-making during analysis. Dr. Matthew Lewis of Bruker highlighted the timsMetabo as a transformative innovation in the field, focusing on customer needs and delivering advanced features for data analysis and quality assurance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.